Envista Holdings Initiated at Equal-Weight by Wells Fargo
Wells Fargo Initiates Envista Holdings(NVST.US) With Hold Rating, Announces Target Price $20
Envista Holdings Is Maintained at Outperform by Evercore ISI Group
Envista Holdings Analyst Ratings
Evercore Maintains Envista Holdings(NVST.US) With Buy Rating, Raises Target Price to $23
Evercore ISI Reaffirms Their Buy Rating on Envista Holdings (NVST)
Evercore ISI Raises Price Target on Envista Holdings to $23 From $18, Keeps Outperform Rating
Analysts Offer Insights on Healthcare Companies: Pyxis Oncology (PYXS), Spruce Biosciences (SPRB) and Envista Holdings (NVST)
Maintaining Hold on Envista Holdings Amid Financial Challenges and Uncertain Recovery
Envista Holdings: Sell Rating Justified by Poor Q2 Performance and Negative FY24 Guidance
Envista Holdings Price Target Cut to $19.00/Share From $22.00 by B of A Securities
Evercore ISI Group Maintains Outperform on Envista Holdings, Lowers Price Target to $18
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Envista Holdings (NVST) and Soleno Therapeutics (SLNO)
Envista Holdings (NVST) Receives a Hold From Piper Sandler
Envista Holdings Analyst Ratings
Envista Holdings: A Cautious Hold Amidst Transition and Anticipated Strategic Insights
UBS Adjusts Envista Price Target to $17 From $22, Maintains Neutral Rating
Envista Holdings Price Target Cut to $16.00/Share From $18.00 by Piper Sandler
Envista Holdings Analyst Ratings
Piper Sandler Maintains Neutral on Envista Holdings, Lowers Price Target to $16